Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00020501 · ClinicalTrials.gov registry record · Phase 3

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

A Phase 3 study of Colorectal Cancer and Metastatic Cancer, sponsored by National Institutes of Health Clinical Center (CC).

Completed
Registry status
Phase 3
Development phase
1
Study location

NCT00020501 is a Phase 3 study of Colorectal Cancer and Metastatic Cancer that has completed, run by National Institutes of Health Clinical Center (CC). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00020501, a Phase 3 study of Colorectal Cancer and Metastatic Cancer, has completed, sponsored by National Institutes of Health Clinical Center (CC).

COMPLETED
Registry status
Phase 3
Development phase
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known which chemotherapy regimen is most effective for colorectal cancer that has spread to the liver. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without isolated hepatic perfusion with melphalan in treating patients who have colorectal cancer that has spread to the liver.

Interventions

  • DRUG fluorouracil
  • DRUG leucovorin calcium
  • DRUG floxuridine
  • DRUG irinotecan hydrochloride
  • DRUG FOLFIRI regimen

Study Locations (1)

Maryland

  • Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda

Trial Details

FieldValue
Start Date 2001-03
Est. Completion 2005-01
Phase Phase 3

What the Registry Record Tells You About NCT00020501

The ClinicalTrials.gov registry entry for NCT00020501 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which fluorouracil is the first listed.

NCT00020501 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00020501 about?

NCT00020501 is a clinical study titled "Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known which chemotherapy regimen is most effective for colorectal cancer tha...

What is the current status of trial NCT00020501?

This trial is currently completed. It is a Phase 3 study. The study started on 2001-03. Estimated completion is 2005-01.

What conditions does trial NCT00020501 study?

This clinical trial studies the following conditions: Colorectal Cancer, Metastatic Cancer.

What interventions are being tested in trial NCT00020501?

The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), floxuridine (DRUG), irinotecan hydrochloride (DRUG), FOLFIRI regimen (DRUG).

Who is sponsoring clinical trial NCT00020501?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00020501 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.